Tracking Canada’s 2015 vaccine research and development priorities: Where are we a decade later?

Read full text Summarise with VIRAT
Authors: Nasheed Moqueet, Kyle Lago, Serena Cortés-Kaplan, Harsimrat Kaur Birdi, Shalini N Desai, Alisha Gauhar, Bryna F. Warshawsky, Matthew C. Tunis, Krista Wilkinson
Cited by: 0
References: 16

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: In 2015, Public Health Agency of Canada (PHAC) identified a set of priorities for research and development (R&D) of new and improved human and animal vaccines.Thirty human pathogens were grouped by vaccine development timeline (short: 0-6 years; medium: 7-12 years; long: 13 years or longer) and ranked by R&D priority (high, medium, low).Objective: To characterize the vaccine development pathway for these 30 pathogens to inform a 2025 update to PHAC's vaccine R&D priorities.Methods: For each pathogen, we conducted a targeted search for vaccines authorized in Canada since 2015 using the Health Canada Drug Product Database and Canadian Immunization Guide and for candidates in clinical trials, in the registry, ClinicalTrials.gov(primary completion date of May 1, 2015 or later).Search results were downloaded and filtered by study status, phase and type.For select pathogens, we conducted additional searches in published (PubMed) and grey literature (other trial registries, industry press releases, and Web searches).Results: Seven pathogens had at least one newly authorized vaccine since 2015: three of 13 high-priority (influenza, n=4; Streptococcus pneumoniae, n=2; respiratory syncytial virus, n=3); two of eight medium-priority (herpes zoster, n=1; meningococcal serogroup B, n=1); and, two of nine low-priority pathogens (dengue, n=2; human papillomavirus, n=1).Nineteen pathogens had no authorized vaccine in Canada or elsewhere, although five had candidates in phase 3 trials (Clostridioides difficile, Neisseria gonorrhoeae, Borrelia burgdorferi, norovirus and cytomegalovirus). Conclusion:Although some of the pathogens on the 2015 list now have authorized vaccines or candidates in late-stage clinical development, important gaps persist, which will inform PHAC's 2025 vaccine R&D update.

Fields of Study & Subjects

Immune responses and vaccinations Bacterial Infections and Vaccines Pharmaceutical Economics and Policy

Publication details

Journal / source
Canada Communicable Disease Report
Volume
52
Issue
3
Pages
97–105
Publication date
26 March 2026
Language
EN